Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison Sells 1,100 Shares

Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael David Garrison also recently made the following trade(s):

• On Wednesday, June 10th, Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $151.48, for a total value of $166,628.00.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock traded up $4.58 during trading hours on Thursday, reaching $152.35. 387,083 shares of the stock traded hands, compared to its average volume of 2,817,616. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35. The firm has a market capitalization of $41.98 billion, a price-to-earnings ratio of 38.56, a P/E/G ratio of 10.19 and a beta of 0.22. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The company has a 50 day moving average price of $148.24 and a 200 day moving average price of $171.15.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. During the same quarter last year, the firm posted $3.35 earnings per share. The firm’s revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Analysts Set New Price Targets

Several analysts have issued reports on BDX shares. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Piper Sandler decreased their price objective on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Wells Fargo & Company lifted their price objective on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. TD Cowen cut their price objective on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a research note on Monday, May 4th. Finally, Stifel Nicolaus decreased their target price on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Seven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus target price of $181.00.

Institutional Investors Weigh In On Becton, Dickinson and Company

A number of institutional investors have recently bought and sold shares of BDX. Auto Owners Insurance Co lifted its position in shares of Becton, Dickinson and Company by 22,225.2% in the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after acquiring an additional 40,528,680 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Becton, Dickinson and Company by 13.0% in the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock worth $7,118,282,000 after purchasing an additional 4,223,149 shares in the last quarter. State Street Corp boosted its stake in Becton, Dickinson and Company by 0.8% in the 4th quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock worth $2,714,871,000 after purchasing an additional 116,737 shares during the period. First Eagle Investment Management LLC grew its holdings in Becton, Dickinson and Company by 16.5% during the 4th quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock valued at $2,260,139,000 after buying an additional 1,651,592 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Becton, Dickinson and Company by 3.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier’s stock valued at $1,841,083,000 after buying an additional 336,110 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.